{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:45:48Z","timestamp":1782899148879,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    The prostate cancer (PCa) treatment landscape, particularly metastatic PCa, is rapidly evolving, with an increase in personalised treatment approaches and therapy selection being guided by tumour genomics. However, PCa remains the third leading cause of death among male-specific cancers in the European Union. Nearly a quarter of patients with metastatic PCa harbour homologous recombination repair (HRR) pathway mutations, with approximately 12% harbouring alterations in the\n                    <jats:italic>BRCA<\/jats:italic>\n                    1 or\n                    <jats:italic>BRCA<\/jats:italic>\n                    2 genes. These genomic alterations are associated with poorer prognosis and increased sensitivity to targeted therapies, such as poly(adenosine diphosphate-ribose) polymerase inhibitors. There is an urgent need to implement HRR and\n                    <jats:italic>BRCA<\/jats:italic>\n                    testing early in the treatment pathway. Despite treatment advances, early testing is not routinely implemented in clinical practice. Barriers include unequal testing access, a lack of clarity on who, when, and how to test, and how to interpret test results accurately. These may prevent eligible patients from receiving treatment early. To address this, we combine our clinical experience with the current literature to support the wider adoption of HRR\/\n                    <jats:italic>BRCA<\/jats:italic>\n                    testing by providing practical recommendations for implementing best practices along the PCa molecular testing pathway. Our recommendations aim to help identify suitable patients for early testing and guide how to obtain, interpret, and utilise molecular test results in clinical decision-making.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1874947","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:47:31Z","timestamp":1782895651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making"],"prefix":"10.3389","volume":"16","author":[{"given":"Eva","family":"Comp\u00e9rat","sequence":"first","affiliation":[{"name":"Department of Pathology, The Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild von","family":"Amsberg","sequence":"additional","affiliation":[{"name":"University Cancer Center Hamburg and Martini-Klinik, University Hospital Hamburg Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Corrigan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tallaght University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Finn","sequence":"additional","affiliation":[{"name":"Cancer Molecular Diagnostics, Trinity St. James's Cancer Institute","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[{"name":"Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut Bergoni\u00e9 Bordeaux","place":["Bordeaux, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102255","article-title":"Testing BRCA 1-2 mutations in metastatic prostate cancer: results of a survey of the Italian Association of Medical Oncology","volume":"23","author":"Saporita","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v8.i1.54","article-title":"Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients","volume":"8","author":"Cui","year":"2020","journal-title":"World J Clin cases"},{"key":"B6","unstructured":"EAU - EANM - ESTRO ESUR - ISUP - SIOG guidelines on prostate cancer\n          \n          \n          \n          2026"},{"key":"B7","unstructured":"Prostate cancer NCCN guidelines\n          \n          \n          \n          2026"},{"key":"B8","unstructured":"Ann oncol\n          \n          \n            \n              Fizazi\n              K\n            \n            \n              Attard\n              G\n            \n            \n              Azad\n              AA\n            \n            \n              Baciarello\n              G\n            \n            \n              Beltran\n              H\n            \n            \n              Bjartell\n              A\n            \n          \n          \n          2026"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.019","article-title":"PRAISE-U Consortium: prostate cancer early detection in the European Union and UK","volume":"87","author":"Leenen","year":"2025","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s40985-018-0080-0","article-title":"Cancer screening recommendations: an international comparison of high income countries","volume":"39","author":"Ebell","year":"2018","journal-title":"Public Health Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/09691413221119238","article-title":"Screening asymptomatic men for prostate cancer: a comparison of international guidelines on prostate-specific antigen testing","volume":"29","author":"Jackson","year":"2022","journal-title":"J Med Screen"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2783","article-title":"A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)","volume":"34","author":"Sandhu","year":"2023","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155803","article-title":"BRCA1 and BRCA2 mutations testing in prostate cancer: detection in formalin fixed paraffin embedded (FFPE) and blood samples","volume":"266","author":"Zannini","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241272929","article-title":"PARP inhibitors alone or in combination for prostate cancer","volume":"16","author":"de la Maza","year":"2024","journal-title":"Ther Adv Urol"},{"key":"B23","unstructured":"Akeega film-coated tablets. Summary of product characteristics\n          \n          \n          2026"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16975","article-title":"The detection of germline and somatic BRCA1\/2 genetic variants through parallel testing of patients with high\u2010grade serous ovarian cancer: a national retrospective audit","volume":"129","author":"Frugniet","year":"2021","journal-title":"BJOG"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2350","article-title":"Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA","volume":"7","author":"Schweizer","year":"2021","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05188-7","article-title":"Real-world data on the prevalence of BRCA1\/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer","volume":"42","author":"Hommerding","year":"2024","journal-title":"World J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac164","article-title":"Concordance between genomic alterations detected by tumor and germline sequencing: results from a tertiary care academic center molecular tumor board","volume":"28","author":"Green","year":"2023","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00329","article-title":"Addition of germline testing to tumor-only sequencing improves detection of pathogenic germline variants in men with advanced prostate cancer","volume":"6","author":"Berchuck","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","volume":"28","author":"Armstrong","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers","volume":"7","author":"Chehade","year":"2024","journal-title":"JAMA Nets Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100588","article-title":"Understanding the uptake and challenges of genetic testing guidelines for prostate cancer patients","volume":"32","author":"Suri","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0009-SA","article-title":"Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine","volume":"143","author":"Compton","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1369\/0022155411398488","article-title":"Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections","volume":"59","author":"Xie","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.203","article-title":"Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer","volume":"7","author":"Gonzalez","year":"2021","journal-title":"J Path Clin Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2014.01.022","article-title":"Tissue fixation and the effect of molecular fixatives on downstream staining procedures","volume":"70","author":"Howat","year":"2014","journal-title":"Methods"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing\u2013based oncology panels","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0156-RA","article-title":"Do more with less: tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the University of Colorado experience","volume":"140","author":"Aisner","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5584-6","article-title":"Targeted capture-based NGS is superior to multiplex PCR-Based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples","volume":"19","author":"Zakrzewski","year":"2019","journal-title":"BMC Cancer"},{"key":"B43","volume-title":"Genomics in the cloud: using docker, gatk, and WDL in terra","author":"van der Geraldine","year":"2020"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am J Hum Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.05.003","article-title":"Circulating biomarkers predictive of treatment response in patients with hormone-sensitive or castration-resistant metastatic prostate cancer: a systematic review","volume":"7","author":"Baboudjian","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104241","article-title":"Blood-based liquid biopsy in advanced prostate cancer","volume":"194","author":"Giunta","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.042","article-title":"Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer","volume":"75","author":"Vandekerkhove","year":"2019","journal-title":"Eur Urol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00631","article-title":"Impact of clonal hematopoiesis-associated mutations in phase I patients treated for solid tumors: an analysis of the STING trial","volume":"8","author":"Rodriguez","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf049","article-title":"Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes","volume":"30","author":"Iranmanesh","year":"2025","journal-title":"Oncologist"},{"key":"B53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"7","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0783-8","article-title":"Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"Li","year":"2020","journal-title":"Genet Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00186","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline clinical insights","volume":"21","author":"Giri","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-02757-0","article-title":"The leading role of pathology in assessing the somatic molecular alterations of cancer: position paper of the European Society of Pathology","volume":"476","author":"Matias-Guiu","year":"2020","journal-title":"Virchows Arch"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-026-00908-0","article-title":"Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective","volume":"14","author":"Xiang","year":"2026","journal-title":"biomark Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:47:45Z","timestamp":1782895665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1874947"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1874947","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1874947"}}